LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article: Resveratrol and liver: A systematic review.

Faghihzadeh, Forouzan / Hekmatdoost, Azita / Adibi, Payman

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

2015 Volume 20, Issue 8, Page(s) 797–810

Abstract: Background: Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. Resveratrol significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ... ...

Abstract	Background: Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. Resveratrol significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ischemia in Wistar rats. It provided liver protection against chemical, cholestatic, and alcohol injury. Resveratrol can improve glucose metabolism and lipid profile and decrease liver fibrosis and steatosis. Furthermore, it was able to alter hepatic cell fatty acid composition. According to extension of liver disease around the world and necessity of finding new threat, this review critically examines the current preclinical in vitro and in vivo studies on the preventive and therapeutic effects of resveratrol in liver disorders. Materials and methods: A search in PubMed, Google Scholar, and Scopus was undertaken to identify relevant literature using search terms, including "liver," "hepatic," and "Resveratrol." Both in vivo and in vitro studies were included. No time limiting considered for this search. Results: A total of 76 articles were eligible for this review. In these articles, resveratrol shows antioxidative properties in different models of hepatitis resulting in reducing of hepatic fibrosis. Conclusion: Resveratrol could reduce hepatic steatosis through modulating the insulin resistance and lipid profile in animals. These high quality preclinical studies propose the potential therapeutic implication of resveratrol in liver disorders especially those with hepatic steatosis. Resveratrol can play a pivotal role in prevention and treatment of liver disorders by reducing hepatic fibrosis.
Language	English
Publishing date	2015-07-29
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2513029-8
ISSN	1735-7136 ; 1735-1995
ISSN (online)	1735-7136
ISSN	1735-1995
DOI	10.4103/1735-1995.168405
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6810: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

Faghihzadeh, Forouzan / Adibi, Payman / Hekmatdoost, Azita

The British journal of nutrition

2015 Volume 114, Issue 5, Page(s) 796–803

Abstract: Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have ...

Abstract	Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.
MeSH term(s)	Adult ; Alanine Transaminase/blood ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Biomarkers/blood ; Blood Pressure/drug effects ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/metabolism ; Dietary Supplements ; Double-Blind Method ; Fatty Liver/blood ; Fatty Liver/complications ; Fatty Liver/drug therapy ; Fatty Liver/metabolism ; Female ; Humans ; Insulin Resistance ; Lipid Metabolism ; Liver/drug effects ; Liver/metabolism ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease/blood ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/metabolism ; Phytotherapy ; Plant Extracts/pharmacology ; Plant Extracts/therapeutic use ; Risk Factors ; Stilbenes/pharmacology ; Stilbenes/therapeutic use ; Triglycerides/blood
Chemical Substances	Anti-Inflammatory Agents ; Antioxidants ; Biomarkers ; Plant Extracts ; Stilbenes ; Triglycerides ; Alanine Transaminase (EC 2.6.1.2) ; resveratrol (Q369O8926L)
Language	English
Publishing date	2015-09-14
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	280396-3
ISSN	1475-2662 ; 0007-1145
ISSN (online)	1475-2662
ISSN	0007-1145
DOI	10.1017/S0007114515002433
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Faghihzadeh, Forouzan / Adibi, Payman / Hekmatdoost, Azita

British journal of nutrition. 2015 Sept., v. 114, no. 5

2015

Abstract	Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P<0·05). BMI, waist circumference, serum aspartate aminotransferase, bilirubin, HDL-cholesterol and apo a1 were reduced significantly in both groups (P<0·05); however, there were no significant differences between the two groups (P>0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.
Keywords	alanine transaminase ; aspartate transaminase ; bilirubin ; blood pressure ; blood serum ; body mass index ; clinical trials ; diet ; fatty liver ; glucose tolerance ; high density lipoprotein cholesterol ; insulin resistance ; noninsulin-dependent diabetes mellitus ; obesity ; patients ; physical activity ; placebos ; resveratrol ; risk factors ; waist circumference
Language	English
Dates of publication	2015-09
Size	p. 796-803.
Publishing place	Cambridge University Press
Document type	Article
ZDB-ID	280396-3
ISSN	1475-2662 ; 0007-1145
ISSN (online)	1475-2662
ISSN	0007-1145
DOI	10.1017/S0007114515002433
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 916: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Resveratrol and liver

Forouzan Faghihzadeh / Azita Hekmatdoost / Payman Adibi

Journal of Research in Medical Sciences, Vol 20, Iss 8, Pp 797-

A systematic review

2015 Volume 810

Abstract	Background: Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. Resveratrol significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ischemia in Wistar rats. It provided liver protection against chemical, cholestatic, and alcohol injury. Resveratrol can improve glucose metabolism and lipid profile and decrease liver fibrosis and steatosis. Furthermore, it was able to alter hepatic cell fatty acid composition. According to extension of liver disease around the world and necessity of finding new threat, this review critically examines the current preclinical in vitro and in vivo studies on the preventive and therapeutic effects of resveratrol in liver disorders. Materials and Methods: A search in PubMed, Google Scholar, and Scopus was undertaken to identify relevant literature using search terms, including "liver," "hepatic," and "Resveratrol." Both in vivo and in vitro studies were included. No time limiting considered for this search. Results: A total of 76 articles were eligible for this review. In these articles, resveratrol shows antioxidative properties in different models of hepatitis resulting in reducing of hepatic fibrosis. Conclusion: Resveratrol could reduce hepatic steatosis through modulating the insulin resistance and lipid profile in animals. These high quality preclinical studies propose the potential therapeutic implication of resveratrol in liver disorders especially those with hepatic steatosis. Resveratrol can play a pivotal role in prevention and treatment of liver disorders by reducing hepatic fibrosis.
Keywords	Antioxidant ; fibrosis ; liver ; liver dysfunction ; liver disorders ; liver transplantation ; nonalcoholic fatty liver ; resveratrol ; steatosis ; Medicine ; R
Subject code	610
Language	English
Publishing date	2015-01-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.

Faghihzadeh, Forouzan / Adibi, Peyman / Rafiei, Rahmatollah / Hekmatdoost, Azita

Nutrition research (New York, N.Y.)

2014 Volume 34, Issue 10, Page(s) 837–843

Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Resveratrol is a polyphenolic compound with antioxidant capacity that shows beneficial effects on down-regulation of inflammatory mediators and metabolic ... ...

Abstract	Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Resveratrol is a polyphenolic compound with antioxidant capacity that shows beneficial effects on down-regulation of inflammatory mediators and metabolic disorders. We hypothesized that supplementation with resveratrol can further improve the efficacy of lifestyle modifications in the management of NAFLD. In this randomized, double-blinded, controlled clinical trial, 50 NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and received physical activity recommendations. Serum liver enzymes, inflammatory markers, hepatic steatosis and fibrosis, dietary intake, anthropometric measurements, and physical activity were assessed at both baseline and the end of the study. In both groups, anthropometric measurements (weight, body mass index, waist circumference), liver enzymes, and steatosis grade improved (P < 005). Resveratrol supplementation was associated with a significant reduction in liver enzyme alanine aminotransferase, inflammatory cytokines, nuclear factor κB activity, serum cytokeratin-18, and hepatic steatosis grade, as compared with placebo supplementation (P < .05). For the treatment of NAFLD, our results showed that 12 weeks of supplementation of 500 mg resveratrol, along with lifestyle modification, is superior to lifestyle modification alone. This is at least partially due to the attenuation of inflammatory markers and hepatocellular apoptosis. More studies are needed to confirm and increase the clinical application of the present results.
MeSH term(s)	Adult ; Alanine Transaminase/blood ; Anthropometry ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Biomarkers/blood ; Cytokines/blood ; Diet ; Dietary Supplements ; Double-Blind Method ; Exercise ; Fatty Liver ; Female ; Humans ; Inflammation Mediators/blood ; Keratin-18/blood ; Liver/drug effects ; Liver/enzymology ; Liver/pathology ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease/blood ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/pathology ; Non-alcoholic Fatty Liver Disease/therapy ; Phytotherapy ; Plant Extracts/pharmacology ; Plant Extracts/therapeutic use ; Polyphenols/pharmacology ; Polyphenols/therapeutic use ; Stilbenes/pharmacology ; Stilbenes/therapeutic use
Chemical Substances	Anti-Inflammatory Agents ; Antioxidants ; Biomarkers ; Cytokines ; Inflammation Mediators ; KRT18 protein, human ; Keratin-18 ; Plant Extracts ; Polyphenols ; Stilbenes ; Alanine Transaminase (EC 2.6.1.2) ; resveratrol (Q369O8926L)
Language	English
Publishing date	2014-10
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	582432-1
ISSN	1879-0739 ; 0271-5317
ISSN (online)	1879-0739
ISSN	0271-5317
DOI	10.1016/j.nutres.2014.09.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1686: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

Faghihzadeh, Forouzan / Azita Hekmatdoost / Peyman Adibi / Rahmatollah Rafiei

Nutrition research. 2014 Oct., v. 34, no. 10

2014

Abstract	Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Resveratrol is a polyphenolic compound with antioxidant capacity that shows beneficial effects on down-regulation of inflammatory mediators and metabolic disorders. We hypothesized that supplementation with resveratrol can further improve the efficacy of lifestyle modifications in the management of NAFLD. In this randomized, double-blinded, controlled clinical trial, 50 NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and received physical activity recommendations. Serum liver enzymes, inflammatory markers, hepatic steatosis and fibrosis, dietary intake, anthropometric measurements, and physical activity were assessed at both baseline and the end of the study. In both groups, anthropometric measurements (weight, body mass index, waist circumference), liver enzymes, and steatosis grade improved (P < 005). Resveratrol supplementation was associated with a significant reduction in liver enzyme alanine aminotransferase, inflammatory cytokines, nuclear factor κB activity, serum cytokeratin-18, and hepatic steatosis grade, as compared with placebo supplementation (P < .05). For the treatment of NAFLD, our results showed that 12 weeks of supplementation of 500 mg resveratrol, along with lifestyle modification, is superior to lifestyle modification alone. This is at least partially due to the attenuation of inflammatory markers and hepatocellular apoptosis. More studies are needed to confirm and increase the clinical application of the present results.
Keywords	alanine transaminase ; antioxidant activity ; apoptosis ; biomarkers ; blood serum ; body mass index ; clinical trials ; cytokines ; fatty liver ; fibrosis ; food intake ; lifestyle ; liver ; metabolic diseases ; patients ; physical activity ; placebos ; resveratrol ; transcription factor NF-kappa B ; waist circumference
Language	English
Dates of publication	2014-10
Size	p. 837-843.
Publishing place	Elsevier Inc.
Document type	Article
ZDB-ID	582432-1
ISSN	1879-0739 ; 0271-5317
ISSN (online)	1879-0739
ISSN	0271-5317
DOI	10.1016/j.nutres.2014.09.005
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 3980: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of Chocolate Consumption on Cardiovascular Risk Factors

Forouzan Faghihzadeh / Ahma Esmaillzadeh

مجله دانشکده پزشکی اصفهان, Vol 28, Iss

Review of Current Evidence

2010 Volume 111

Abstract: Background: Due to controversies in different studies about the effects of dark chocolate consumption on cardiovascular risk factors, this study aimed to review the current evidence on chocolate consumption and cardiovascular risk factors. Methods: By ... ...

Abstract	Background: Due to controversies in different studies about the effects of dark chocolate consumption on cardiovascular risk factors, this study aimed to review the current evidence on chocolate consumption and cardiovascular risk factors. Methods: By the use of dark chocolate, dark chocolate and cardiovascular disease, and dark chocolate and atherosclerosis, as keywords, we searched in PubMed through 1990 till 2008. Just clinical trials on apparently healthy people or those suffering from lipid disorders were included. Results: In most studies, consumption of chocolates with plant sterols induced a reduction in serum total cholesterol and LDL in hypercholesterolemic individuals. Positive effects of dark chocolate on reduction of platelet aggregation has been reported in some investigations while others found neutral effects of white and dark chocolate on platelet aggregation. The effect of dark chocolate intake on insulin sensitivity and reduction of insulin resistance are mentioned in some but not all studies. Dark chocolate consumption significantly reduced blood pressure. A reduction in biomarkers of oxidative stress like 8-isoprostane and MDA has also been reported in some trials. Conclusion: Most of the clinical trials indicated favorable effects of dark chocolate and cocoa consumption on cardiovascular risk factors. More research is needed to identify the related mechanisms of action. Key words: Chocolate, Cardiovascular disease, Hypertension, Polyphenols.
Keywords	Medicine ; R ; Medicine (General) ; R5-920
Subject code	610
Language	Persian
Publishing date	2010-11-01T00:00:00Z
Publisher	Vesnu Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Faghihzadeh, Forouzan / Payman AdibiauthorIntegrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan 81744, Iran / Azita HekmatdoostauthorDepartment of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran 19395-4741, Iran

Language	English
Document type	Article
Database	AGRIS - International Information System for the Agricultural Sciences and Technology

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED